Targeting HCV entry for development of therapeutics

Viruses

Volumn 2, Issue 8, 2010, Pages 1718-1733

  Wong Staal, F ^a   Syder, Andrew J ^a   Mckelvy, Jeffrey F ^a  

^a ITherX Pharmaceuticals   (United States)

Author keywords

HCV entry inhibitors; HCVpp; SR BI; Therapeutics development

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; ARABIDOL; CD81 ANTIGEN; CELGOSOVIR; CLAUDIN 1; CYANOVIRIN N; GLYCOSAMINOGLYCAN; HEPATITIS C VIRUS ENTRY INHIBITOR; INTERFERON; ITX 4520; ITX 5061; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; OCCLUDIN; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PLACEBO; PRADIMICIN A; PRO 206; RIBAVIRIN; SCAVENGER RECEPTOR B; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; CELL SURFACE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; ENDOCYTOSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; MOLECULAR DOCKING; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS PARTICLE; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 79952173517     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2081718     Document Type: Review

References (81)

1. Falck-Ytter, Y.; Kale, H.; Mullen, K.D.; Sarbah, S.A.; Sorescu, L.; McCullough, A.J. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann. Intern. Med. 2002, 136, 288-292.
2. Lohmann, V.; Korner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
3. Bartosch, B.; Dubuisson, J.; Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functionalE1-E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633-642.
4. Hsu, M.; Zhang, J.; Flint, M.; Logvinoff, C.; Cheng-Mayer, C.; Rice, C.M.; McKeating, J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 7271-7276.
5. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Krausslich, H.G.; Mizokami, M.; Bartenschlager, R.; Liang, T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791-796.
6. Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wolk, B.; Tellinghuisen, T. L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; Rice, C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623-626.
7. Zhong, J.; Gastaminza, P.; Cheng, G.; Kapadia, S.; Kato, T.; Burton, D.R.; Wieland, S.F.; Uprichard, S.L.; Wakita, T.; Chisari, F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 9294-9299.
8. Gastaminza, P.; Cheng, G.; Wieland, S.; Zhong, J.; Liao, W.; Chisari, F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008, 82, 2120-2129.
9. Modi, A.A.; Hoofnagle, J.H. New therapies for hepatitis C. Hepatology 2007, 46, 615-617.
10. Thompson, A.J.; McHutchison, J.G. Review article: investigational agents for chronic hepatitis C. Aliment. Pharmacol. Ther. 2009, 29, 689-705.
11. Behrens, S.E.; Tomei, L.; De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 1996, 15, 12-22.
12. Shudo, E.; Ribeiro, R.M.; Perelson, A.S. Modeling HCV kinetics under therapy using PK and PD information. Expert. Opin. Drug Metab. Toxicol. 2009, 5, 321-332.
13. Manns, M.P.; Foster, G.R.; Rockstroh, J.K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment--finding the right path. Nat. Rev. Drug Discov. 2007, 6, 991-1000.
14. van der Valk, M.; Reiss, P.; van Leth, F.C.; Ackermans, M.T.; Endert, E.; Romijn, J.A.; Heijligenberg, R.; Sauerwein, H. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J. Clin. Endocrinol. Metab. 2002, 87, 5066-5071.
15. McHutchison, J.G.; Everson, G.T.; Gordon, S.C.; Jacobson, I.M.; Sulkowski, M.; Kauffman, R.; McNair, L.; Alam, J.; Muir, A.J. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360, 1827-1838.
16. Lindenbach, B.D.; Rice, C.M. Molecular biology of flaviviruses. Adv. Virus Res. 2003, 59, 23-61.
17. Fletcher, N.F.; Yang, J.P.; Farquhar, M.J.; Hu, K.; Davis, C.; He, Q.; Dowd, K.; Ray, S.C.; Krieger, S.E.; Neyts, J.; Baumert, T.F.; Balfe, P.; McKeating, J.A.; Wong-Staal, F. Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology 2010.
18. Deleersnyder, V.; Pillez, A.; Wychowski, C.; Blight, K.; Xu, J.; Hahn, Y.S.; Rice, C.M.; Dubuisson, J. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 1997, 71, 697-704.
19. Patel, A.H.; Wood, J.; Penin, F.; Dubuisson, J.; McKeating, J.A. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J. Gen. Virol. 2000, 81, 2873-2883.
20. Cocquerel, L.; Wychowski, C.; Minner, F.; Penin, F.; Dubuisson, J. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J. Virol. 2000, 74, 3623-3633.
21. Brazzoli, M.; Helenius, A.; Foung, S.K.; Houghton, M.; Abrignani, S.; Merola, M. Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology 2005, 332, 438-453.
22. Krey, T.; d'Alayer, J.; Kikuti, C.M.; Saulnier, A.; Damier-Piolle, L.; Petitpas, I.; Johansson, D.X.; Tawar, R. G.; Baron, B.; Robert, B.; England, P.; Persson, M.A.; Martin, A.; Rey, F.A. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010, 6, e1000762.
23. Farci, P.; Shimoda, A.; Wong, D.; Cabezon, T.; De Gioannis, D.; Strazzera, A.; Shimizu, Y.; Shapiro, M.; Alter, H.J.; Purcell, R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 15394-15399.
24. Forns, X.; Thimme, R.; Govindarajan, S.; Emerson, S.U.; Purcell, R.H.; Chisari, F.V.; Bukh, J. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 13318-13323.
25. Scarselli, E.; Ansuini, H.; Cerino, R.; Roccasecca, R.M.; Acali, S.; Filocamo, G.; Traboni, C.; Nicosia, A.; Cortese, R.; Vitelli, A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21, 5017-5025.
26. Andre, P.; Komurian-Pradel, F.; Deforges, S.; Perret, M.; Berland, J. L.; Sodoyer, M.; Pol, S.; Brechot, C.; Paranhos-Baccala, G.; Lotteau, V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 2002, 76, 6919-6928.
27. Søren U.; Nielsen, M.F.B.; Alastair D.; Burt, C.M.; Pumeechockchai, W.; Toms, G.L. Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients J. Virol. 2006, 80, 2418-2428.
28. Bartosch, B.; Verney, G.; Dreux, M.; Donot, P.; Morice, Y.; Penin, F.; Pawlotsky, J.M.; Lavillette, D.; Cosset, F.L. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 2005, 79, 8217-8229.
29. Voisset, C.; Op de Beeck, A.; Horellou, P.; Dreux, M.; Gustot, T.; Duverlie, G.; Cosset, F.L.; Vu-Dac, N.; Dubuisson, J. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J. Gen. Virol. 2006, 87, 2577-2581.
30. Lindenbach, B.D.; Rice, C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436, 933-938.
31. Barth, H.; Schnober, E.K.; Zhang, F.; Linhardt, R.J.; Depla, E.; Boson, B.; Cosset, F.L.; Patel, A.H.; Blum, H.E.; Baumert, T.F. Viral and cellular determinants of the hepatitis C virus envelopeheparan sulfate interaction. J. Virol. 2006, 80, 10579-10590.
32. Koutsoudakis, G.; Kaul, A.; Steinmann, E.; Kallis, S.; Lohmann, V.; Pietschmann, T.; Bartenschlager, R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 2006, 80, 5308-5320.
33. Molina, S.; Castet, V.; Fournier-Wirth, C.; Pichard-Garcia, L.; Avner, R.; Harats, D.; Roitelman, J.; Barbaras, R.; Graber, P.; Ghersa, P.; Smolarsky, M.; Funaro, A.; Malavasi, F.; Larrey, D.; Coste, J.; Fabre, J.M.; Sa-Cunha, A.; Maurel, P. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 2007, 46, 411-419.
34. Owen, D.M.; Huang, H.; Ye, J.; Gale, M., Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009, 394, 99-108.
35. Rigotti, A.; Miettinen, H.E.; Krieger, M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr. Rev. 2003, 24, 357-387.
36. Catanese, M.T.; Ansuini, H.; Graziani, R.; Huby, T.; Moreau, M.; Ball, J.K.; Paonessa, G.; Rice, C.M.; Cortese, R.; Vitelli, A.; Nicosia, A. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 2010, 84, 34-43.
37. Dreux, M.; Dao Thi, V.L.; Fresquet, J.; Guerin, M.; Julia, Z.; Verney, G.; Durantel, D.; Zoulim, F.; Lavillette, D.; Cosset, F.L.; Bartosch, B. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 2009, 5, e1000310.
38. Bartosch, B.; Vitelli, A.; Granier, C.; Goujon, C.; Dubuisson, J.; Pascale, S.; Scarselli, E.; Cortese, R.; Nicosia, A.; Cosset, F.L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 2003, 278, 41624-41630.
39. Levy, S.; Shoham, T. The tetraspanin web modulates immune-signalling complexes. Nat. Rev. Immunol. 2005, 5, 136-148.
40. Pileri, P.; Uematsu, Y.; Campagnoli, S.; Galli, G.; Falugi, F.; Petracca, R.; Weiner, A.J.; Houghton, M.; Rosa, D.; Grandi, G.; Abrignani, S. Binding of hepatitis C virus to CD81. Science 1998, 282, 938-941.
41. Zhang, J.; Randall, G.; Higginbottom, A.; Monk, P.; Rice, C.M.; McKeating, J.A. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 2004, 78, 1448-1455.
42. Cormier, E.G.; Durso, R.J.; Tsamis, F.; Boussemart, L.; Manix, C.; Olson, W.C.; Gardner, J.P.; Dragic, T. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 14067-14072.
43. Akazawa, D.; Date, T.; Morikawa, K.; Murayama, A.; Miyamoto, M.; Kaga, M.; Barth, H.; Baumert, T.F.; Dubuisson, J.; Wakita, T. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 2007, 81, 5036-5045.
44. Cormier, E.G.; Tsamis, F.; Kajumo, F.; Durso, R.J.; Gardner, J.P.; Dragic, T. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 7270-7274.
45. McKeating, J.A.; Zhang, L.Q.; Logvinoff, C.; Flint, M.; Zhang, J.; Yu, J.; Butera, D.; Ho, D.D.; Dustin, L.B.; Rice, C.M.; Balfe, P. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J. Virol. 2004, 78, 8496-8505.
46. Grove, J.; Brimacombe, C.; Syder, A.J.; Flores, N.V.; Krieger, S.E.; Timpe, J.M.; Baumert, T.F.; Tellinghuisen, T.L.; Wong-Staal, F.; Balfe, P.; McKeating, J.A. Neutralizing antibody resistant hepatitis C virus transmission. In Society of General Microbiology, Edinburgh, UK, 2010.
47. Evans, M.J.; von Hahn, T.; Tscherne, D.M.; Syder, A.J.; Panis, M.; Wolk, B.; Hatziioannou, T.; McKeating, J.A.; Bieniasz, P.D.; Rice, C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446, 801-805.
48. Harris, H.J.; Farquhar, M.J.; Mee, C.J.; Davis, C.; Reynolds, G.M.; Jennings, A.; Hu, K.; Yuan, F.; Deng, H.; Hubscher, S.G.; Han, J.H.; Balfe, P.; McKeating, J.A., CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J. Virol. 2008, 82, 5007-5020.
49. Reynolds, G.M.; Harris, H.J.; Jennings, A.; Hu, K.; Grove, J.; Lalor, P.F.; Adams, D.H.; Balfe, P.; Hubscher, S.G.; McKeating, J.A. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 2008, 47, 418-427.
50. Harris, H.J.; Davis, C.; Mullins, J.G.; Hu, K.; Goodall, M.; Farquhar, M.J.; Mee, C. J.; McCaffrey, K.; Young, S.; Drummer, H.; Balfe, P.; McKeating, J.A., Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 2010. M110.104836
51. Ploss, A.; Evans, M.J.; Gaysinskaya, V.A.; Panis, M.; You, H.; de Jong, Y.P.; Rice, C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457, 882-886.
52. Liu, S.; Yang, W.; Shen, L.; Turner, J.R.; Coyne, C.B.; Wang, T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009, 83, 2011-2014.
53. Benedicto, I.; Molina-Jimenez, F.; Bartosch, B.; Cosset, F.L.; Lavillette, D.; Prieto, J.; Moreno-Otero, R.; Valenzuela-Fernandez, A.; Aldabe, R.; Lopez-Cabrera, M.; Majano, P.L., The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J. Virol. 2009, 83, 8012-8020.
54. Kohaar, I.; Ploss, A.; Korol, E.; Mu, K.; Schoggins, J.W.; O'Brien, T.R.; Rice, C.M.; Prokunina-Olsson, L. Splicing diversity of human OCLN gene and its biological significance for hepatitis C virus (HCV) entry. J. Virol. 2010, 84, 6987-6994
55. Blanchard, E.; Belouzard, S.; Goueslain, L.; Wakita, T.; Dubuisson, J.; Wychowski, C.; Rouille, Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80, 6964-6972.
56. Meertens, L.; Bertaux, C.; Dragic, T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 2006, 80, 11571-11578.
57. Coller, K.E.; Berger, K.L.; Heaton, N.S.; Cooper, J.D.; Yoon, R.; Randall, G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009, 5, e1000702.
58. Tscherne, D.M.; Jones, C.T.; Evans, M.J.; Lindenbach, B.D.; McKeating, J.A.; Rice, C.M. Timeand temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 2006, 80, 1734-1741.
59. Koutsoudakis, G.; Herrmann, E.; Kallis, S.; Bartenschlager, R.; Pietschmann, T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 2007, 81, 588-598.
60. Bowen, D.G.; Walker, C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436, 946-952.
61. Law, M.; Maruyama, T.; Lewis, J.; Giang, E.; Tarr, A.W.; Stamataki, Z.; Gastaminza, P.; Chisari, F.V.; Jones, I.M.; Fox, R.I.; Ball, J.K.; McKeating, J.A.; Kneteman, N.M.; Burton, D.R. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14, 25-27.
62. von Hahn, T.; Yoon, J.C.; Alter, H.; Rice, C.M.; Rehermann, B.; Balfe, P.; McKeating, J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132, 667-678.
63. Liang, Y.; Shilagard, T.; Xiao, S.Y.; Snyder, N.; Lau, D.; Cicalese, L.; Weiss, H.; Vargas, G.; Lemon, S.M. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 2009, 137, 1448-1458.
64. Durantel, D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs 2009, 10, 860-870.
65. Boriskin, Y.S.; Pecheur, E.I.; Polyak, S.J. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol. J. 2006, 3, 56.
66. Helle, F.; Wychowski, C.; Vu-Dac, N.; Gustafson, K.R.; Voisset, C.; Dubuisson, J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 2006, 281, 25177-25183.
67. Matsumura, T.; Hu, Z.; Kato, T.; Dreux, M.; Zhang, Y.Y.; Imamura, M.; Hiraga, N.; Juteau, J.M.; Cosset, F.L.; Chayama, K.; Vaillant, A.; Liang, T.J. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009, 137, 673-681.
68. Zeisel, M.B.; Barth, H.; Schuster, C.; Baumert, T.F. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front. Biosci. 2009, 14, 3274-3285.
69. Meuleman, P.; Hesselgesser, J.; Paulson, M.; Vanwolleghem, T.; Desombere, I.; Reiser, H.; Leroux-Roels, G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008, 48, 1761-1768.
70. Syder, A.J.; Lee, H.; Zeisel, M.B.; Grove, J.; Soulier, E.; Macdonald, J.; Chow, S.; Chang, J.; Baumert, T.F.; McKeating, J.A.; McKelvy, J.; Wong-Staal, F. Small Molecule Scavenger Receptor BI Antagonists are Potent HCV Entry Inhibitors J. Hepatol. 2010, in press.
71. Grove, J.; Nielsen, S.; Zhong, J.; Bassendine, M.F.; Drummer, H.E.; Balfe, P.; McKeating, J.A. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 2008, 82, 12020-12029.
72. Masson, D.; Koseki, M.; Ishibashi, M.; Larson, C.J.; Miller, S.G.; King, B.D.; Tall, A.R. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler. Thromb Vasc. Biol. 2009, 29, 2054-2060.
73. McKelvy, J.; Lee, H.; Syder, A.J.; Chang, J.; Macdonald, J.; Wong-Staal, F. ITX5061, an orally bioavailable, clinical stage compound, targets scavenger receptor BI to inhibit HCV entry. In 16th Int. Symp. on Hepatitis C Virus & Related Viruses, Nice, France, 2009.
74. Luchoomun, J.V.; Villegas, D; Killion, S; Hirst, T; Adelman, S; Collins, H; Hellerstein, M; Turner, S. Differential effects of SR-B1 inhibition on reverse cholesterol transport pathways in CETP and non-CETP species. In American Heart Association Meetings Abstracts, 2010.
75. Yang, J.P.; Zhou, D.; Wong-Staal, F. Screening of small-molecule compounds as inhibitors of HCV entry. Methods Mol. Biol. 2009, 510, 295-304.
76. Wong-Staal, F.; Liu, G.; McKelvy, J. HCV Viral Entry Inhibitors. In Antiviral Drugs: Biology, Chemistry, Clinic; Kazmierski, W.M., Ed.; John Wiley and Sons: Hoboken, New Jersey, USA, in press.
77. Qian, D.C., Coburn G.A.; Han, A.Q.; de Muys, J.M.; Gauss, C; Provoncha, K; Canfield, M; Paul, D; Mohamed, S; Moorji, S; Fisch, D; Murga, J; Rotshteyn, Y; Maddon, P.J.; Olson, W.C. Preclinical characterization of PRO 206, an orally active HCV entry inhibitor. In EASL 44th Annual Meeting, Copenhagen, Denmark, 2009.
78. De Muys, J. M. Coburn, G.A.; Han, A.; Provoncha, K.; Paul, D.; Moorji, S.; Fisch, D.; Murga, J.; Qian, D.C.; Maddon, P.J.; Olson, W.C. Discovery of potent and selective inhibitors of Hepatitis C virus (HCV) entry. In 16th Int. Symp. on Hepatitis C Virus & Related Virus, Nice, France, 2009.
79. Ge, D.; Fellay, J.; Thompson, A.J.; Simon, J.S.; Shianna, K.V.; Urban, T.J.; Heinzen, E.L.; Qiu, P.; Bertelsen, A.H.; Muir, A.J.; Sulkowski, M.; McHutchison, J.G.; Goldstein, D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461, 399-401.
80. Gane, E.J.; Portmann, B.C.; Naoumov, N.V.; Smith, H.M.; Underhill, J.A.; Donaldson, P.T.; Maertens, G.; Williams, R. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 1996, 334, 815-820.
81. Rowe, I.A.; Webb, K.; Gunson, B.K.; Mehta, N.; Haque, S.; Neuberger, J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl. Int. 2008, 21, 459-465.